Key result
SGLT2 inhibitors cut cardiovascular events ~25% in prediabetes with CVD or heart failure.
Why the study?
Prediabetes affects a large global population and increases cardiovascular risk, yet comprehensive evidence on the cardiovascular effects of various interventions in this population remained limited.
Do glucose-lowering, antihypertensive, lipid-lowering, lifestyle, and nutritional interventions reduce cardiovascular events in adults with prediabetes?
Systematic Review
Do glucose-lowering, antihypertensive, lipid-lowering, lifestyle, and nutritional interventions reduce cardiovascular events in adults with prediabetes?
Cardiovascular benefits in adults with prediabetes are primarily limited to secondary prevention using SGLT2 inhibitors, semaglutide, or pravastatin in those with established heart failure or cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Supports targeted SGLT2 inhibitor or statin use in prediabetes with comorbidities; extends RCT data but leaves primary prevention gaps unresolved.
Background: Prediabetes affects a huge global population and markedly increases subsequent cardiovascular risk. Despite the growing burden, comprehensive evidence on the cardiovascular effects of various interventions remains limited. This systematic review aims to evaluate the cardiovascular benefits of a broad range of interventions conducted in randomized controlled trials in patients with prediabetes. Methods: We systematically searched MEDLINE, Embase, and Cochrane Library from inception to 13 August 2026 for randomized controlled trials (≥12 weeks follow-up) conducted in patients with prediabetes. Studies involving pregnant women or individuals under 18 years of age were excluded. The primary outcomes were any cardiovascular events, including coronary heart disease, myocardial infarction, stroke, heart failure, peripheral vascular disease, acute coronary syndromes, revascularization, atrial fibrillation, and CVD hospitalization or death. Two investigators independently conducted study selection, data extraction, and risk of bias assessment. Given substantial heterogeneity across studies, narrative synthesis was performed instead of meta-analysis. Results: We identified 22 studies (25 publications), with sample sizes ranging from 20 to 11,696 participants (median age 63 years) followed up for a median of 3.3 years. Interventions encompassed glucose-lowering, antihypertensive, lipid-lowering, lifestyle, and nutritional approaches. SGLT-2 inhibitors reduced hospitalization for heart failure compared with placebo, including dapagliflozin (RR 0.75, 95% CI 0.58–0.98, p = 0.036) and empagliflozin (RR 0.75, 95% CI 0.60–0.93, p = 0.010) in patients with prediabetes and heart failure. Semaglutide reduced major adverse cardiovascular events in patients with prediabetes, pre-existing cardiovascular disease, and overweight. Evidence on acarbose treatment remained inconclusive. Antihypertensive drugs showed no significant cardiovascular benefits in patients with prediabetes with comorbid hypertension, CVD, or other risk factors, whereas lipid-lowering therapy with pravastatin significantly reduced cardiovascular events in patients with prediabetes with a history of myocardial infarction or unstable angina (RR 0.81, 95% CI 0.70–0.95, p = 0.008). Lifestyle and nutritional interventions lacked sufficient evidence to reduce CVD risk. Conclusion: Current evidence suggests that cardiovascular benefits of interventions in adults with prediabetes are modest and dependent on both comorbidity profiles and intervention types, with some benefits observed for SGLT2 inhibitors, semaglutide and pravastatin in reducing cardiovascular events for secondary prevention. These findings highlight substantial evidence gaps and the need for dedicated cardiovascular outcome trials in patients with prediabetes.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) conducted a systematic review in Prediabetes. Glucose-lowering (SGLT2 inhibitors, semaglutide, acarbose), antihypertensive, lipid-lowering (pravastatin), lifestyle, and nutritional interventions vs. Placebo or control was evaluated on Any cardiovascular events, including coronary heart disease, myocardial infarction, stroke, heart failure, peripheral vascular disease, acute coronary syndromes, revascularization, atrial fibrillation, and CVD hospitalization or death (RR 0.75, 95% CI 0.58-0.98, p=0.036). SGLT2 inhibitors, semaglutide, and pravastatin reduced CV events in prediabetes with established CVD or HF.
Synapse has enriched 10 related papers. Consider them for comparative context: